BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 28778341)

  • 21. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
    Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
    Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Surgical Management of Advanced Stages of Borderline Ovarian Tumours].
    Raimond E; Bourdel N
    Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):304-313. PubMed ID: 32004785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Chevrot A; Pouget N; Bats AS; Huchon C; Guyon F; Chopin N; Rousset-Jablonski C; Beurrier F; Lambaudie E; Provansal M; Sabatier R; Heinemann M; Ngo C; Bonsang-Kitzis H; Lecuru F; Bailly E; Ferron G; Cornou C; Lardin E; Leblanc E; Philip CA; Ray-Coquard I; Hequet D
    Gynecol Oncol; 2020 Apr; 157(1):29-35. PubMed ID: 32241341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group.
    du Bois A; Ewald-Riegler N; de Gregorio N; Reuss A; Mahner S; Fotopoulou C; Kommoss F; Schmalfeldt B; Hilpert F; Fehm T; Burges A; Meier W; Hillemanns P; Hanker L; Hasenburg A; Strauss HG; Hellriegel M; Wimberger P; Keyver-Paik MD; Baumann K; Canzler U; Wollschlaeger K; Forner D; Pfisterer J; Schröder W; Münstedt K; Richter B; Kommoss S; Hauptmann S;
    Eur J Cancer; 2013 May; 49(8):1905-14. PubMed ID: 23490647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopathological analysis of borderline ovarian tumours and risk factors related to recurrence: experience of single institution.
    Sozen H; Vatansever D; Topuz S; Iyibozkurt C; Kandemir H; Yalçin I; Onder S; Yavuz E; Salihoglu Y
    J Obstet Gynaecol; 2019 Feb; 39(2):253-258. PubMed ID: 30372646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Retrospective analysis of the clinical outcomes in 12 recurrent borderline ovarian tumor patients with second fertility-sparing surgery].
    Chen R; Zhu T; Yu H; Zhu J; Lu X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Apr; 49(4):254-9. PubMed ID: 24969331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fertility preservation in women with borderline ovarian tumors - how does it impact disease outcome? A cohort study.
    Helpman L; Yaniv A; Beiner ME; Aviel-Ronen S; Perri T; Ben-Baruch G; Hogen Ben-David L; Jakobson-Setton A; Korach J
    Acta Obstet Gynecol Scand; 2017 Nov; 96(11):1300-1306. PubMed ID: 28815550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The feasibility of fertility-sparing surgery in treating advanced-stage borderline ovarian tumors: A meta-analysis.
    Huang Y; Zhang W; Wang Y
    Taiwan J Obstet Gynecol; 2016 Jun; 55(3):319-25. PubMed ID: 27343308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study.
    Fauvet R; Demblocque E; Morice P; Querleu D; Daraï E
    Ann Surg Oncol; 2012 Mar; 19(3):941-7. PubMed ID: 21879267
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Unilateral borderline ovarian tumor and unilateral adenexectomy?].
    Boujenah J; Bricou A; Moreaux G; Grynberg M; Sifer C; Hugues JN; Poncelet C
    Gynecol Obstet Fertil; 2014 Sep; 42(9):635-9. PubMed ID: 25164163
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnancy outcome and recurrence after conservative laparoscopic surgery for borderline ovarian tumors.
    Tinelli FG; Tinelli R; La Grotta F; Tinelli A; Cicinelli E; Schönauer MM
    Acta Obstet Gynecol Scand; 2007; 86(1):81-7. PubMed ID: 17230294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Pointers for Surgical Staging of Borderline Ovarian Tumors.
    Bendifallah S; Nikpayam M; Ballester M; Uzan C; Fauvet R; Morice P; Darai E
    Ann Surg Oncol; 2016 Feb; 23(2):443-9. PubMed ID: 26442919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
    Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
    Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Borderline ovarian tumors: outcomes of fertility sparing surgery.
    Ozalp SS; Yalcin OT; Telli E; Oge T; Kabukcuoglu S
    Eur J Gynaecol Oncol; 2014; 35(2):154-6. PubMed ID: 24772918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
    Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
    Falcone F; Malzoni M; Carnelli M; Cormio G; De Iaco P; Di Donato V; Ferrandina G; Raspagliesi F; Sorio R; Losito NS; Greggi S
    Gynecol Oncol; 2022 May; 165(2):302-308. PubMed ID: 35232587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrence and prognostic factors in borderline ovarian tumors.
    Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
    Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of factors that impact recurrence in patients with borderline ovarian tumors.
    Chen X; Fang C; Zhu T; Zhang P; Yu A; Wang S
    J Ovarian Res; 2017 Apr; 10(1):23. PubMed ID: 28376898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.